Abstract:Objective To explore RIZ1 mRNA expression level in different subtypes and risk classification groups of the patients with myelodysplastic syndromes (MDS) and to analyze the correlation between the clinical features and RIZ1 mRNA expression. Methods A total of 46 newly diagnosed as MDS patients and 10 healthy controls who were the donors of hematopoietic stem cell transplantation from Chuiyangliu Hospital Affiliated to Tsinghua University and the Second Hospital of Shanxi Medical University between January 2014 and December 2017 were collected. The real time fluorescence quantitative polymerase chain reaction (RT-PCR) was used to detect the expression level of RIZ1 mRNA in bone marrow cells from MDS patients and the healthy controls. Results Compared with the healthy control group, the relative expression level of RIZ1 mRNA in MDS patients was decreased [the median (P25, P75):1.003 (0.895, 1.812) vs. 0.557 (0.333, 0.815)], and the difference was statistically significant (Z= -2.991, P= 0.0003). According tothe World Health Organization (WHO) classification criteria, compared with the healthy control group, the relative expression of RIZ1 mRNA in refractory anemia/refractory anemia with ring sideroblasts/refractory cytopenia with multiple dysplasia (RA/RAS/RCMD), refractory anemia with excess blasts Ⅰ (RAEB-Ⅰ), RAEB-Ⅱand MDS transformed into acute myeloid leukemia (MDS/AML) groups had statistically significant differences (χ2= 19.500, P< 0.01). Further pairwise comparison showed that the relative expression level of RIZ1 mRNA in RAEB-Ⅰ, RAEB-Ⅱand MDS/AML groups was lower than that in the healthy control group, and the differences were statistically significant (all P < 0.05). According to the international prognostic scoring system (IPSS), compared with the healthy control group, the expression of RIZ1 mRNA in low-risk, inter-risk-1, inter-risk-2 and high-risk group had statistical differences (χ2= 19.214, P= 0.001). Further pairwise comparison showed that the relative expression of RIZ1 mRNA in inter-risk-1, inter-risk-2 and high risk group was lower than that in the healthy control group, and the differences were statistically significant (all P<0.05). And RIZ1 mRNA expression showed a decreasing trend with the increase of disease risk grade. RIZ1 mRNA expression level had no relationship with age, gender, peripheral blood white cell count, the hemoglobin, platelet count and karyotype (all P> 0.05). Conclusion RIZ1 mRNA expression level is decreased in MDS patients, and it is different in various subtypes and risk classification. RIZ1 may involve in the pathogenesis of MDS and play an important role in the progression of MDS.

Over-expression of RPL23 in myelodysplastic syndromes is associated with apoptosis resistance of CD34 + cells and predicts poor prognosis and distinct response to CHG chemotherapy or decitabine

Ribosomal Protein L23 Negatively Regulates Cell Apoptosis Via Its Suppression of Miz1 and Activation C-Myc in Higher-Risk Myelodysplastic Syndromes

Ribosomal Protein L23 Negatively Regulates Cellular Apoptosis Via the RPL23/Miz-1/C-Myc Circuit in Higher-Risk Myelodysplastic Syndrome

Expression and Clinical Significance of Phospholipase D1 in De Novo Acute Myeloid Leukemia

G Protein-Coupled Receptor 183 Plays a Prognostic Factor in Acute Myeloid Leukemia by Regulating Immune Regulation

Low RPS14 Expression in MDS Without 5q - Aberration Confers Higher Apoptosis Rate of Nucleated Erythrocytes and Predicts Prolonged Survival and Possible Response to Lenalidomide in Lower Risk Non-5Q- Patients.

Low Expression of RPS14 Accompanied with P53-Independent Over-Apoptosis in Myelodysplastic Syndromes Patients with 5Q- Aberration

Study On the Expression of 14-3-3ζ in Acute Myeloid Leukemic Cell Lines

Low RPS14 gene expression is accompanied by p53-independent apoptosis in MDS patients with 5q- aberrations

RPL22L1 is a novel biomarker for prognosis and immune infiltration in lung adenocarcinoma, promoting the growth and metastasis of LUAD cells by inhibiting the MDM2/P53 signaling pathway

Expression and Clinical Significance of RAG1 in Myelodysplastic Syndromes

High Expression of Mir-25 Predicts Favorable Chemotherapy Outcome in Patients with Acute Myeloid Leukemia.

Research of Gene Expression in Patients with Myelodysplastic Syndromes.

Low RPS14 Expression in MDS without 5q- Aberration Is Associated with Increased Apoptosis of Erythrocytes and Predicts Prolonged Survival and Possible Response to Lenalidomide in Lower-Risk Patients

Over-expression of CD200 predicts poor prognosis in MDS

Increased Expression Of Circulating Mir-22 In The Peripheral Blood Of Patients With Myelodysplastic Syndromes Was Associated With Poorer Prognosis

Ribosomal Proteins S13 and L23 Promote Multidrug Resistance in Gastric Cancer Cells by Suppressing Drug-Induced Apoptosis*1

RSL3 enhances ROS-mediated cell apoptosis of myelodysplastic syndrome cells through MYB/Bcl-2 signaling pathway

Dysregulation of miR-138-5p/RPS6KA1-AP2M1 Is Associated With Poor Prognosis in AML

FLT3-ITD and MLL-PTD influence the expression of MDR-1, MRP-1, and BCRP mRNA but not LRP mRNA assessed with RQ-PCR method in adult acute myeloid leukemia

Expression of RIZ1 gene in myelodysplastic syndromes and its significance